KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Operating Leases (2019 - 2025)

Alnylam Pharmaceuticals' Operating Leases history spans 7 years, with the latest figure at $225.1 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 1.94% year-over-year to $225.1 million; the TTM value through Dec 2025 reached $225.1 million, down 1.94%, while the annual FY2025 figure was $225.1 million, 1.94% down from the prior year.
  • Operating Leases reached $225.1 million in Q4 2025 per ALNY's latest filing, up from $223.4 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $288.6 million in Q2 2021 to a low of $223.4 million in Q3 2025.
  • Average Operating Leases over 5 years is $253.5 million, with a median of $250.6 million recorded in 2023.
  • Peak YoY movement for Operating Leases: rose 4.44% in 2021, then dropped 8.32% in 2024.
  • A 5-year view of Operating Leases shows it stood at $281.3 million in 2021, then fell by 7.11% to $261.3 million in 2022, then decreased by 6.98% to $243.1 million in 2023, then fell by 5.58% to $229.5 million in 2024, then decreased by 1.94% to $225.1 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Operating Leases are $225.1 million (Q4 2025), $223.4 million (Q3 2025), and $224.4 million (Q2 2025).